anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides an external preparation for treating chilblain, which is characterized in that the external preparation is prepared from the raw materials: 7 to 12 wt% of honeysuckle, 4 to 8 wt% of herba houttuyniae, 70 to 85 wt% of japanese pepper and 4 to 10 wp% of garlic and is added with the alcohol containing 2 to 3% of iodine. The quantity of the alcohol is four to six times of that of the japanese pepper. The preparation can quickly activate capillaries at the affected position and promote the blood circulation at the position, so active components in the preparation, which have effects of activating blood circulation, dissipating blood stasis, eliminating inflammation, alleviating pain, cooling, detoxification, detumescence, alleviating itch, dredging channels, etc. enter the deep part of the affected position through epidermal cells. Symptoms of itch, pain and flare are quickly lightened, are improved for several days and are even cured. The preparation also has the characteristics of convenient use, no toxic or side effect, no greasiness, no pollution, obvious effect, etc.
BACKGROUND: Vertebral compression fractures (VCFs) are typically treated nonoperatively but can be treated with either kyphoplasty or vertebroplasty when indicated. The decision to treat patients with/without surgical intervention is dependent on the severity of deformity and patient risk profile. The aims of this study were to: 1) compare baseline patient demographics, 2) identify risk factors of patients undergoing operative vs. nonoperative management, and 3) identify patient-specific risk factors associated with postoperative readmissions.
METHODS: This retrospective database study used patient information from January 1st, 2010, to October 31st, 2021. Cohorts were identified by patients diagnosed with VCFs through International Classification of Disease, Ninth Revision (ICD-9), ICD-10 codes, identifying those undergoing kyphoplasty/vertebroplasty via Current Procedural Terminology codes. The 2 research domains utilized in this investigation were baseline demographic profiles of patients who underwent kyphoplasty or vertebroplasty for treatment of VCFs, and those who underwent nonoperative management served as the control cohort.
RESULTS: Of the 703,499 patients diagnosed with VCFs, 76,126 patients (10.8%) underwent kyphoplasty or vertebroplasty within 90 days of diagnosis of a VCF. Univariate analysis demonstrated female sex was associated with increased risk of undergoing surgical management for VCF (P < 0.0001). Several comorbidities were significantly associated with increased rates of readmission including hypertension, tobacco use, coronary artery disease, and chronic obstructive pulmonary disease (P < 0.0001 for all).
CONCLUSIONS: This study highlights specific comorbidities that are significantly associated with higher rates of kyphoplasty or vertebroplasty for the treatment of thoracolumbar wedge compression fractures and increased risk for 90-day postoperative hospital readmission.
Repetitive Strain Injury (RSI) or Work-Related Musculoskeletaldisorders (WRMD) are the names given to skeletal muscle disorders that mainly affect the upper limbs, the scapular region and the neck. One of the most affected categories is nursing workers who present health problems inherent to the function they perform in their daily activities. Due to this peculiarity, several studies are focused on the occupational risks of nursing workers in the hospital environment. However, It was not found in the literature studies that suggests strategies to prevent and improve the worker's quality of life. Distance education comes as a differential. It has power in interactive media and collaborative learning beyond self-learning and mass media. This research project proposes to carry out a randomized clinical trial where the intervention group will receive a Prevention Course in RSI/WRMD in the distance education modality and the control group will receive Educational Lectures on Prevention in RSI /WRMD, both groups will be composed by a nursing team from the Clinical Hospital of Porto Alegre.
BACKGROUND & AIM: Extracorporeal shock wave lithotripsy (ESWL) is used for the treatment of pancreatic duct stones (PDS) in patients with chronic pancreatitis (CP). We aimed to develop a CT based index to predict the required number of ESWL sessions for technical success.
METHODS: We retrospectively evaluated patients with PDS secondary to CP who underwent ESWL. Technical success was defined as the complete fragmentation of stones to <3 mm. CT features including PDS size, number, location, and density in Hounsfield units (HU) were noted. We analyzed the relationship between PDS characteristics and the number of ESWL sessions required for technical success. A multiple linear regression model was used to combine size and density into the pancreatic duct stone (PDS) index that was translated into a web-based calculator.
RESULTS: There were 206 subjects (mean age 38.6 ± 13.7 years, 59.2% male) who underwent ESWL. PDS size showed a moderate correlation with the number of ESWL sessions (r = 0.42, p < 0.01). PDS in the head required a fewer number of sessions in comparison to those in the body (1.4 ± 0.6 vs. 1.6 ± 0.7, p = 0.01). There was a strong correlation between PDS density and the number of ESWL sessions (r = 0.617, p-value <0.01). The PDS index {0.3793 + [0.0009755 x PDS density (HU)] + [0.02549 x PDS size (mm)]} could accurately predict the required number of ESWL sessions with an AUC of 0.872 (p < 0.01).
CONCLUSION: The PDS index is a useful predictor of the number of ESWL sessions needed for technical success that can help in planning and patient counseling.
Metastasis causes greater than 90% of cancer-associated deaths, presenting huge challenges for detection and efficient treatment of cancer due to its high heterogeneity and widespread dissemination to various organs. Therefore, it is imperative to combat cancer metastasis, which is the key to achieving complete cancer eradication. Immunotherapy as a systemic approach has shown promising potential to combat metastasis. However, current clinical immunotherapies are not effective for all patients or all types of cancer metastases owing to insufficient immune responses. In recent years, immunological nanomaterials with intrinsic immunogenicity or immunomodulatory agents with efficient loading have been shown to enhance immune responses to eliminate metastasis. In this review, we would like to summarize various types of immunological nanomaterials against metastasis. Moreover, this review will summarize a series of immunological nanomaterial-mediated immunotherapy strategies to combat metastasis, including immunogenic cell death, regulation of chemokines and cytokines, improving the immunosuppressive tumour microenvironment, activation of the STING pathway, enhancing cytotoxic natural killer cell activity, enhancing antigen presentation of dendritic cells, and enhancing chimeric antigen receptor T cell therapy. Furthermore, the synergistic anti-metastasis strategies based on the combinational use of immunotherapy and other therapeutic modalities will also be introduced. In addition, the nanomaterial-mediated imaging techniques (e.g., optical imaging, magnetic resonance imaging, computed tomography, photoacoustic imaging, surface-enhanced Raman scattering, radionuclide imaging, etc.) for detecting metastasis and monitoring anti-metastasis efficacy are also summarized. Finally, the current challenges and future prospects of immunological nanomaterial-based anti-metastasis are also elucidated with the intention to accelerate its clinical translation.
PURPOSE: A pharmaceutical composition containing a rice wine filter cake extract for preventing and treating allergy is provided to suppress allergen secretion from mast cells and to relieve allergic symptom. CONSTITUTION: A pharmaceutical composition for preventing and treating allergic diseases contains a rice wine filter cake extract as an active ingredient. The composition is manufactured in the form of a capsule, a tablet, granules, an injection, an ointment, a powder, or a beverage. The allergic diseases are allergic dermatitis, allergic rhinitis, allergic asthma, allergic tympanitis, anaphylatic shock, or allergic conjunctivitis. The pharmaceutical composition suppresses allergen secretion. A health functional food for preventing and treating allergic diseases contains the rice wine filter cake extract as an active ingredient. A cosmetic composition for preventing and treating allergic diseases contains the rice wine filter cake extract as an active ingredient. [Reference numerals] (AA) Antigen; (BB) Emission of beta-hexosaminidase(O.D); (CC) Fermented products of rice wine filter cake extracts(ug/ml)
The NIH has called for testing promising implementation strategies (PAR-19-274) and there is a critical need for implementation and sustainment of effective and evidence-based practices (EBPs) to address health conditions including substance use disorders (SUDs) which are among the most complex of public health issues. The proposed project is consistent with NIDA's Priority Focus Area "Strategies to improve the effective and sustainable implementation of evidence-based prevention and treatment interventions (implementation science)." Most implementation strategies do not address the complex multilevel context for implementation in public service sectors, but rather focus on direct service providers. This proposed project will expand the Leadership and Organizational Change for Implementation (LOCI) organizational change strategy for EBP implementation and sustainment, to address the larger outer system context in which SUD treatment organizations operate through engaging state policy and funding stakeholders along with community-based behavioral health agencies to understand and work toward aligning state-level policies and with organizational implementation improvement strategies. The project will focus on implementation and sustainment of the Lyssn artificial intelligence (AI) quality assurance platform along with implementation of Motivational Interviewing (MI). Consistent with the Exploration, Preparation, Implementation, Sustainment (EPIS) framework and system and organizational theory, the investigators will add a system level component to LOCI with the goal of bridging outer and inner context and developing and aligning a positive implementation climate to support implementation and sustainment of Lyssn and MI in SUD treatment agencies. The study will use mixed qualitative and quantitative methods in a stepped-wedge design to examine change in implementation leadership and implementation climate as a function the LOCI-SL intervention as well as exploring subsequent Lyssn and MI sustainment. The study will also include a "scaling-out" aim in which data from this study will be used to compare proposed mediational pathways (i.e., mechanisms) with data from a prior study. The study will involve ongoing engagement with state policy and funding stakeholders and qualitative examination of ways to facilitate academic-policy collaborations to enhance EBP implementation and sustainment.
Pioglitazone

A total of 92 patients (15.2%) treated with pioglitazone in the three pooled 16- to 26-week double-blind, placebo-controlled, monotherapy trials were ≥65 years old and 2 patients (0.3%) were ≥75 years old. In the two pooled 16- to 24-week add-on to sulfonylurea trials, 201 patients (18.7%) treated with pioglitazone were ≥65 years old and 19 (1.8%) were ≥75 years old. In the two pooled 16- to 24-week add-on to metformin trials, 155 patients (15.5%) treated with pioglitazone were ≥65 years old and 19 (1.9%) were ≥75 years old. In the two pooled 16- to 24-week add-on to insulin trials, 272 patients (25.4%) treated with pioglitazone were ≥65 years old and 22 (2.1%) were ≥75 years old.

In PROactive Trial, 1,068 patients (41%) treated with pioglitazone were ≥65 years old and 42 (1.6%) were ≥75 years old.

In pharmacokinetic studies with pioglitazone, no significant differences were observed in pharmacokinetic parameters between elderly and younger patients [see CLINICAL PHARMACOLOGY (12.3)].

Although clinical experiences have not identified differences in effectiveness and safety between the elderly (≥65 years) and younger patients, these conclusions are limited by small sample sizes for patients ≥75 years old.

Metformin hydrochloride

Controlled clinical studies of metformin did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients, although other reported clinical experience has not identified differences in responses between the elderly and young patients. Metformin is known to be substantially excreted by the kidney and because the risk of serious adverse reactions to the drug is greater in patients with impaired renal function, pioglitazone and metformin hydrochloride should only be used in patients with normal renal function [see CONTRAINDICATIONS (4), WARNINGS AND PRECAUTIONS (5.2), and CLINICAL PHARMACOLOGY (12.3)]. Because aging is associated with reduced renal function, pioglitazone and metformin hydrochloride should be used with caution as age increases. Care should be taken in dose selection and should be based on careful and regular monitoring of renal function. Generally, elderly patients should not be titrated to the maximum dose of pioglitazone and metformin hydrochloride [see WARNINGS AND PRECAUTIONS (5.2) and DOSAGE AND ADMINISTRATION (2)].
The investigators objective is to study effects of a contraceptive vaginal ring (CVR) containing estrogen and progesterone (NuvaRing) on vaginal bacteria, HIV shedding, and local immunity in women. The investigators will build on data that support a favorable effect of CVR on vaginal bacteria. Bacterial vaginosis (BV) is found in \>50% of women in sub-Saharan Africa. BV significantly increases risk of HIV acquisition in, and HIV transmission to male partners from, HIV-infected women, genital HIV shedding, and viral set point in infected male partners. Pregnancy is also an independent risk for HIV acquisition and transmission. Contraception comprises critical biomedical prevention for women with or at risk for HIV. Systemic depot progesterone-commonly used throughout Africa-may independently increase risk of HIV acquisition and transmission. Hormonal interventions preventing unintended pregnancy and promoting a protective vaginal microenvironment could synergistically reduce HIV risk especially combined with topical antiretrovirals (ARV). The investigators propose NuvaRing use may contribute to reduction in BV, pregnancy prevention, and decreased rates of HIV shedding in HIV-infected women. Sustained vaginal delivery of contraceptive and ARV PrEP as "multicomponent prevention" is a major focus for scientists but effects on the vaginal environment need careful definition before broad implementation.

Total duration of follow up is no more than 8 months, with 5 months of CVR usage.
An in vivo free-radical generator comprising silver ions supported on a specified carrier. It generates free radicals .OH in the presence of water. When supported on an ion-exchanger, the silver ions release gradually .OH radicals in the presence of water. The released .OH radicals act on cancer cells to thereby suppress the cell growth and disrupt the cells, thus making cancer therapy possible. When zeolite or silica gel is used as the carrier in an amount below a specified value, the carrier is innocuous for the human body and can readily be excreted. Thus this generator is suitable as a medicine which is brought to the target tissue in the living body, such as a cancer cell, and generates free radicals thereat for long without adversely affecting the other tissues so much.
Initial loading dosing of warfarin for the first 3 days of treatment will be determined by the Taiwan algorithm that uses clinical and genetic information. Dose adjustment after initiation will using guideline modified from Tait el al. (1998).
The study is a multicenter, adaptive, randomized, double-blinded, and placebo-controlled Phase II/III trial. It will be conducted globally. The study will evaluate the efficacy and safety of SCTA01 compared to placebo both given with BSC in participants with severe COVID-19. The subjects will be randomized by 1:1 ratio to SCTA01 and placebo group. The primary objective of the study is to evaluate participant survival from randomization to Day 29 between study group and control group. At the end of the Phase II part of the study, an interim analysis will be performed for safety run-in and futility stopping.
PROBLEM TO BE SOLVED: To obtain the subject agent having safety and strongly improving effects on motor function of digestive tract, capable of improving the complain of general malaise of abdomen and the feeling of fullness of a patient having reduced motor function of various digestive tracts by including glutamine as an active ingredient. SOLUTION: This improver contains glutamine as an active ingredient. Glutamine is generally used in the form of a free amino acid and may be used in the form a salt, a peptide or the like. A metal salt or an acid addition salt can be used as the salt. An alkali metal salt is preferable as the salt. When glutamine is used together with another amino acid such as taurine or the like, preferably more improved effects are obtained. In the case of oral administration, the improver is preferably administered in the dosage of 0.05-0.3 g/kg/day. The improver is preferably administered once to several times dividedly in the dosage.
Inflammatory pain, sustained by a complex network of inflammatory mediators, is a severe and persistent illness affecting many of the general population. We explore possible anti-inflammatory pathways of Polyphyllin VI (PPVI) based on our prior study, which showed that PPVI reduces inflammation in mice to reduce pain. Network pharmacology and RNA-Seq identified the contribution of the MAPK signaling pathway to inflammatory pain. In the LPS/ATP-induced RAW264.7 cell model, pretreatment with PPVI for 1 h inhibited the release of IL-6 and IL-8, down-regulated expression of the P2X7 receptor(P2X7R), and decreased phosphorylation of p38 and ERK1/2 components of the MAPK pathway. Moreover, PPVI decreased expression of IL-6 and IL-8 was observed in the serum of the inflammatory pain mice model and reduced phosphorylation of p38 and ERK1/2 in the dorsal root ganglia while the reductions of expression of IL-6 and phosphorylation of ERK1/2 were not observed after the pre-treatment with A740003 (an antagonist of the P2X7R). These results suggest that PPVI may inhibit the release of IL-8 by regulating P2X7R to reduce the phosphorylation of p38. However, the modulation of PPVI on the release of IL-6 and phosphorylation of ERK1/2 may mediated by other P2X7R-independent signals.
Social Virtual Reality will be delivered using virtual reality glasses for 30-45 minutes during dialysis sessions. Groups of 3 participants will watch a movie or program together through the glasses. They will be able to talk and interact during the session.
Activated phosphoinositide 3-kinase delta syndrome (APDS) is an inborn error of immunity with heterogeneous clinical manifestations of infections, immune dysregulation, autoimmunity; lymphoproliferation; and malignancy. Immune complex-mediated vasculitides have not yet been described in APDS patients. Here we offer a case series of three patients with APDS who have refractory IgA vasculitis (also called Henoch-Schönlein purpura), a form of immune complex-mediated vasculitis that activates complement and attracts neutrophils, macrophages and eosinophils to cause local tissue injury. Leniolisib is an inhibitor of PI3K p110δ and an FDA-approved treatment for APDS. IgA vasculitis resolved upon treatment with leniolisib. Patients with immune dysregulation including IgA vasculitis should be screened for APDS.
There is a high prevalence of cigarette smoking among people with schizophrenia and few smoking cessation interventions have been developed for these individuals. Bupropion is an antidepressant medication commonly used to treat smoking in smokers without psychiatric disorder. This study compares how smokers with schizophrenia and smokers without psychiatric illness respond to bupropion (0, 300 mg/day).

Participants will be randomly assigned to receive either bupropion or placebo. Study visits will occur after one-week treatment with placebo or bupropion. During study sessions, participants will come to the laboratory at 9 am and will remain abstinent in the laboratory for 5 hrs. Participants will then be assessed for craving and withdrawal symptoms after viewing and handling neutral cues and smoking cues. After that, participants will have a 90-min period to smoke, and smoking topography will be measured.
PROBLEM TO BE SOLVED: To obtain a pharmaceutical preparation containing an unstable physiologically active substance in stable state. SOLUTION: This freeze-dried preparation contains 1 pt.wt. of a physiologically active substance having a (substituted) amidino group and expressed by formula (R is H or an alkyl; X is H or an alkyl; Y is a cyclic hydrocarbon group; Z is carboxyl) or its salt and 1-1,000 pts.wt., preferably 5-500 pts.wt. of a disaccharide such as galactose, lactose or sucrose. It can be produced by dissolving both components in water or an aqueous solvent (e.g. an alcohol) and freeze-drying the aqueous solution by conventional method. An example of the compound of formula is (S)-4-(4-amidinobenzoylglycyl)-3- methoxycarbonylmethyl-2-oxopiperazine-1-acetic acid. It can be administered by oral or parenteral administration as an agent for the treatment of cerebral thrombosis (acute stage), cerebral ischemic syndrome, unstable angina, etc.
Composites resins have become the first choice for direct anterior and posterior restorations. The great popularity is related to their esthetic appearance and reduced need of sound tissue removal as compared with former treatments. Several studies have demonstrated that composite restorations may last long in clinical service. Composite restorations have demonstrated a good clinical performance with annual failure rates varying from 1% to 3% in posterior teeth and 1% to 5% in anterior teeth.
The invention relates to veterinary immunology, namely to a method for enhancing immune response in vaccination of animals against such infections as anthrax and blackleg. The invention is aimed at solving the problem of creating a method for increasing immunogenicity of vaccines against anthrax and blackleg due to simultaneous reduction of immunising dose and reactogenicity of vaccines. The method is realised in the following way. Healthy animals (guinea pigs) are immunised with either anti-anthrax vaccine based on anthrax avirulent strain Bacillus anthracis 55 SSNINRRIVV&M or anti-blackleg vaccine based on inactivated culture of virulent strain of blackleg, with each of vaccines being diluted with isotonic solution of sodium chloride with concentration 0.85-0.95% in ratio not higher than 1:9 and injected subcutaneously in dose 0.4-0.6 ml per unit. Immunomodulator is injected to animals subcutaneously 30-40 min after immunisation. As immunomodulator used is preparation in form of mixture of aqueous formaldehyde solution of 36.5-40.0% concentration and isotonic sodium chloride solution of 0.85-0.95% concentration with ratio of constituent parts of solutions equal 2-6:994-998.